Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Viral risks associated with blood transfusion]

F Barin1

  • 1Laboratoire de Virologie, URA CNRS 1334, CHRU Bretonneau et UFR Sciences Pharmaceutiques, Tours.

Revue Francaise De Transfusion Et D'Hemobiologie : Bulletin De La Societe Nationale De Transfusion Sanguine
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Tetherin, a cell protein which inhibits HIV-1 release from infected cells, is antagonized by the protein Vpu].

Virologie (Montrouge, France)·2022
Same author

[TRIM5α and susceptibility of the human species to an extinct retrovirus].

Virologie (Montrouge, France)·2022
Same author

[Origin of pandemic and nonpandemic HIVs].

Virologie (Montrouge, France)·2021
Same author

[Virologie is 10 years old].

Virologie (Montrouge, France)·2021
Same author

[HIV diversity: the need for surveillance].

Virologie (Montrouge, France)·2021
Same author

[Early resistance to adefovir during treatment of a chronic hepatitis B].

Virologie (Montrouge, France)·2021
Same journal

[Recombinant immunoglobulins].

Revue francaise de transfusion et d'hemobiologie : bulletin de la Societe nationale de transfusion sanguine·1993
Same journal

[HLA-DRB1 and HLA-DQB1 polymorphism in Algerians from Algiers].

Revue francaise de transfusion et d'hemobiologie : bulletin de la Societe nationale de transfusion sanguine·1993
Same journal

Comparative study of human monoclonal anti-D antibodies of IgG and IgM classes in tests with red cells of nonhuman primates.

Revue francaise de transfusion et d'hemobiologie : bulletin de la Societe nationale de transfusion sanguine·1993
Same journal

[A sickle cell homozygote with transfusion deadlock. Favorable outcome with hydroxyurea treatment].

Revue francaise de transfusion et d'hemobiologie : bulletin de la Societe nationale de transfusion sanguine·1993
Same journal

[The nomenclature of immunohematologic records:in favor of an evolution of biologic and medical practices].

Revue francaise de transfusion et d'hemobiologie : bulletin de la Societe nationale de transfusion sanguine·1993
Same journal

[Reduction of the post-transfusion hepatitis C risk in patients undergoing bone marrow allograft].

Revue francaise de transfusion et d'hemobiologie : bulletin de la Societe nationale de transfusion sanguine·1993
See all related articles

Blood transfusions carry a risk of transmitting viruses like hepatitis and HIV from asymptomatic donors. While screening has reduced risks, some infectious units may be missed, especially during silent incubation periods.

Area of Science:

  • Virology
  • Transfusion Medicine
  • Public Health

Background:

  • Blood transfusions pose a risk of transmitting infectious agents from asymptomatic donors.
  • Hepatitis viruses (HBV, HCV) and retroviruses (HIV, HTLV) are primary transfusion-transmitted pathogens.
  • While screening has improved, residual risks remain due to limitations in detecting all infectious stages.

Purpose of the Study:

  • To review the current landscape of transfusion-transmitted viral infections.
  • To highlight the effectiveness and limitations of existing screening methods for blood donations.
  • To discuss the implications of viral incubation periods and infectivity in the context of blood safety.

Main Methods:

  • Review of existing literature on transfusion-transmitted viruses.

Related Experiment Videos

  • Analysis of screening strategies for hepatitis B, hepatitis C, HIV, and HTLV.
  • Discussion of the impact of viral incubation periods on transfusion safety.

    • Main Results:

    • Screening for HBsAg, ALT, HBc Ab, HCV Ab, HIV Ab, and HTLV Ab has significantly reduced transmission risks.
    • Immunoassays for HCV, HIV, and HTLV primarily detect antibodies, potentially missing infectious units during early incubation.
    • Human cytomegalovirus (HCMV) and parvovirus B19 are common infections, posing risks in specific populations like pregnant women and the immunocompromised.

    Conclusions:

    • Current blood screening methods have substantially decreased transfusion-related hepatitis and retroviral infections.
    • A residual risk of transfusion transmission exists due to antibody-based screening and undetected viral presence during incubation.
    • Further vigilance and potentially advanced screening methods are necessary to mitigate risks from viruses like HCMV and parvovirus B19.